Metabolic Profile and Anthropometric Changes in Schizophrenia

Condition(s) targeted: Metabolic Syndrome; Diabetes; Obesity

Intervention: Olanzapine (Drug); Risperidone (Drug); Haloperidol (Drug)

Phase: N/A

Status: Completed

Sponsored by: Central Institute of Psychiatry, Ranchi, India

Official(s) and/or principal investigator(s):
Sahoo Saddichha, DPM, Principal Investigator, Affiliation: Central Institute of Psychiatry

"No clinical differences will be found between the three antipsychotics under study -

olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "

Official title: Metabolic Profile and Anthropometric Changes in Schizophrenia

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening

Primary outcome: Study of metabolic profile

Secondary outcome: Study of obesity and diabetes

Detailed description: we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.

Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age between 18-40 years

- Diagnosis of schizophrenia

- Drug naive on admission

Exclusion Criteria:

- Other psychiatric co-morbidity

- History of severe physical illness

- Alcohol and substance abuse or dependence

- History of pre-existing diabetes or hypertension

- Family history of hypertension or diabetes

Central Institute of Psychiatry, Ranchi 834009, India

Starting date: June 2006
Last updated: September 21, 2007